Dr. Brahmer on 5-Year Follow-Up Data for Nivolumab in NSCLC

Julie R. Brahmer, MD
Published: Monday, Apr 03, 2017


Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses 5-year follow-up data from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC).
 
Approximately 129 NSCLC patients with metastatic disease were enrolled in the trial, all of whom had previously been treated with up to 5 lines of prior therapy. The patients were randomized to 3 different doses of nivolumab, given once every 2 weeks for up to 2 years.
 
The estimated 5-year overall survival (OS) for this group of patients was 16%. This is an improvement from historical data, Brahmer explains, which showed a 5-year OS of approximately 4% in patients who were treated for metastatic disease with standard treatment.
 

Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses 5-year follow-up data from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC).
 
Approximately 129 NSCLC patients with metastatic disease were enrolled in the trial, all of whom had previously been treated with up to 5 lines of prior therapy. The patients were randomized to 3 different doses of nivolumab, given once every 2 weeks for up to 2 years.
 
The estimated 5-year overall survival (OS) for this group of patients was 16%. This is an improvement from historical data, Brahmer explains, which showed a 5-year OS of approximately 4% in patients who were treated for metastatic disease with standard treatment.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x